Related Experiment Video

Updated: May 2, 2026

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.1K

IL-15 Agonists: The Cancer Cure Cytokine

Jennifer Wu1

  • 1Department of Microbiology and Immunology, Medical university of South Carolina, Charleston, SC ; Cancer Immunology Program, Hollings Cancer Center, Charleston, SC ; Department of Medicine, University of Washington, Seattle, WA.

Journal of Molecular and Genetic Medicine : an International Journal of Biomedical Research
|March 4, 2014
PubMed

Insights

Interleukin-15 (IL-15) shows promise as a cancer therapy by supporting immune cells. New IL-15 agonists, combining IL-15 with its receptor, aim to enhance its effectiveness in treating solid tumors.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Interleukin-15 (IL-15) is a cytokine recognized for its potential in cancer treatment.
  • IL-15 is crucial for the survival of natural killer (NK), natural killer-like T (NKT), and memory CD8 T cells.
  • IL-15 exerts its in vivo bioactivity primarily through trans-presentation with the soluble IL-15 receptor (IL-15Rα).

Purpose of the Study:

  • To review the key features of IL-15 as a cancer treatment cytokine.
  • To summarize recent developments in IL-15 agonists and preclinical studies.
  • To highlight critical milestones for translating preclinical findings to clinical application.

Main Methods:

  • Literature review of IL-15's role in cancer immunology.
  • Analysis of recent studies on IL-15 agonists.
  • Evaluation of preclinical data for IL-15-based cancer therapies.

Main Results:

  • IL-15 agonists, engineered to improve in vivo bioactivity, are a focus of recent research.
  • Preclinical studies are exploring the efficacy of IL-15 and its agonists against metastatic solid tumors.
  • Understanding IL-15's trans-presentation mechanism is key to developing effective agonists.

Conclusions:

  • IL-15 is a promising cytokine for cancer immunotherapy, particularly for solid tumors.
  • Development of IL-15 agonists represents a significant advancement in enhancing IL-15's therapeutic potential.
  • Further research and strategic planning are necessary to bridge the gap between preclinical development and patient treatment.
Keywords:
Cancer therapyCytokineInterleukin-15

More Related Videos

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

1.7K
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

9.6K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K